| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial M Kudo, RS Finn, S Qin, KH Han, K Ikeda, F Piscaglia, A Baron, JW Park, ... The Lancet 391 (10126), 1163-1173, 2018 | 5188 | 2018 |
| The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 5046 | 2018 |
| An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ... Cell 173 (2), 400-416. e11, 2018 | 3102 | 2018 |
| Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018 | 2850 | 2018 |
| Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018 | 2439 | 2018 |
| Cabozantinib in patients with advanced and progressing hepatocellular carcinoma GK Abou-Alfa, T Meyer, AL Cheng, AB El-Khoueiry, L Rimassa, BY Ryoo, ... New England Journal of Medicine 379 (1), 54-63, 2018 | 2361 | 2018 |
| Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ... Cell 173 (2), 291-304. e6, 2018 | 2290 | 2018 |
| Comprehensive and integrative genomic characterization of hepatocellular carcinoma A Ally, M Balasundaram, R Carlsen, E Chuah, A Clarke, N Dhalla, RA Holt, ... Cell 169 (7), 1327-1341. e23, 2017 | 2093 | 2017 |
| Machine learning identifies stemness features associated with oncogenic dedifferentiation TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ... Cell 173 (2), 338-354. e15, 2018 | 1863 | 2018 |
| Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma J Bridgewater, PR Galle, SA Khan, JM Llovet, JW Park, T Patel, TM Pawlik, ... Journal of hepatology 60 (6), 1268-1289, 2014 | 1667 | 2014 |
| Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study JW Park, M Chen, M Colombo, LR Roberts, M Schwartz, PJ Chen, ... Liver International 35 (9), 2155-2166, 2015 | 1300 | 2015 |
| Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas TA Knijnenburg, L Wang, MT Zimmermann, N Chambwe, GF Gao, ... Cell reports 23 (1), 239-254. e6, 2018 | 1021 | 2018 |
| Genomic and functional approaches to understanding cancer aneuploidy AM Taylor, J Shih, G Ha, GF Gao, X Zhang, AC Berger, SE Schumacher, ... Cancer cell 33 (4), 676-689. e3, 2018 | 989 | 2018 |
| Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images J Saltz, R Gupta, L Hou, T Kurc, P Singh, V Nguyen, D Samaras, ... Cell reports 23 (1), 181-193. e7, 2018 | 960 | 2018 |
| The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma CJ Ricketts, AA De Cubas, H Fan, CC Smith, M Lang, E Reznik, R Bowlby, ... Cell reports 23 (1), 313-326. e5, 2018 | 926 | 2018 |
| Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... The lancet oncology 23 (1), 77-90, 2022 | 896 | 2022 |
| Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial AL Cheng, YK Kang, DY Lin, JW Park, M Kudo, S Qin, HC Chung, X Song, ... Journal of clinical oncology 31 (32), 4067-4075, 2013 | 874 | 2013 |
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study PJ Johnson, S Qin, JW Park, RTP Poon, JL Raoul, PA Philip, CH Hsu, ... Journal of clinical oncology 31 (28), 3517-3524, 2013 | 872 | 2013 |
| Comprehensive analysis of alternative splicing across tumors from 8,705 patients A Kahles, KV Lehmann, NC Toussaint, M Hüser, SG Stark, ... Cancer cell 34 (2), 211-224. e6, 2018 | 846 | 2018 |
| Pathogenic germline variants in 10,389 adult cancers K Huang, RJ Mashl, Y Wu, DI Ritter, J Wang, C Oh, M Paczkowska, ... Cell 173 (2), 355-370. e14, 2018 | 796 | 2018 |
